News

Ascendis Pharma (NasdaqGS:ASND) has regained exclusive rights to TransCon technology-based products in metabolic and cardiovascular diseases after ending its collaboration with Novo Nordisk. The company plans to advance its own programs in obesity and type 2 diabetes using its TransCon platform. Management highlighted once-monthly TransCon Semaglutide as a planned program within its expanded metabolic disease pipeline. The regained TransCon metabolic and cardiovascular rights and plans for...

The consumer health company’s GLP-1 shelf strategy at CVS is paying off, and bigger retailers could follow.

Eli Lilly stakes its trillion-dollar valuation on mid-stage data for a two-drug obesity combo, and the September 30 readout will reveal whether eloraTZP is a genuine franchise leap or an expensive gamble on incremental gains.

Novo Nordisk A/S (NYSE:NVO) decision to use “Novo” as its day-to-day name is part of a broader attempt by CEO Mike Doustdar to reset the company’s culture and sharpen its competitive focus. The rebrand comes as Novo tries to regain momentum in obesity drugs after losing ground to Eli Lilly. Doustdar’s new “Novo Way” emphasizes […]

Novo (formerly Novo Nordisk) is partnering with Anthropic to use AI to speed up drug discovery.

NVO's denecimig wins a positive European opinion for hemophilia A, with flexible dosing and a potential 2026 launch.

↘️ Nestle (CH:NESN): The Swiss food-product maker said it is assessing options for its Russian unit after Moscow transferred control to external administrators, in the latest move by the Kremlin to seize the local assets of international companies.

The approval for its generic version of Novo Nordisk’s blockbuster drug advances its efforts to build a portfolio of GLP-1 medicines.

On September 7, 2026, Reuters reported that Novo Nordisk A/S (NYSE:NVO) halted two additional trials of its experimental cardiovascular drug ziltivekimab, further denting the Danish drugmaker’s efforts to diversify beyond its blockbuster obesity and diabetes franchise. The move follows a July disclosure that ziltivekimab failed to reduce major adverse cardiovascular events in a late-stage trial. […]

The fresh trigger for Novo Nordisk (CPSE:NOVO B) is a CHMP green light for FREHEMGO, a haemophilia A therapy that could add a rare-disease revenue stream alongside its core obesity and diabetes portfolio. Novo Nordisk has packed several catalysts into September, yet the share price tells a different story, with a 30 day share price return of down 5.7% and a year to date share price return of down 15.4% despite today’s 2.5% one day gain to DKK279.35. Over a longer stretch, the total...

Ascendis Pharma A/S (NASDAQ:ASND) announced on September 14 that it will regain exclusive rights to develop, manufacture, and commercialize TransCon products in metabolic and cardiovascular diseases following the termination of its collaboration with Novo Nordisk A/S (NYSE:NVO). The rights include once-monthly TransCon Semaglutide, an investigational long-acting prodrug of semaglutide intended for obesity and type 2 […]

Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index adding 0.8% and the S

A European regulatory recommendation puts a new hemophilia treatment within reach of its first commercial launch.

The Committee for Medicinal Products for Human Use recommended European Union marketing authorization for Frehemgo in adults and children with haemophilia A on Thursday.

Healthcare stocks rose Thursday afternoon, with the NYSE Healthcare Index adding 0.5% and the State

On August 31, 2026, Reuters reported on a new study finding that patients who stay on the lowest starter doses of GLP-1 weight-loss drugs still lose weight, though far less than at full recommended doses, and experience less nausea. Patients on Eli Lilly and Company (NYSE:LLY)’s low-dose tirzepatide lost an average of 5.5% of their […]

LLY's GLP-1 momentum, Foundayo launch and retatrutide pipeline support growth, but premium valuation and rising competition weigh on the stock.

NVO is expanding its AI strategy with Anthropic to tackle drug discovery challenges, boost R&D productivity and develop new medicines faster.

NVO's 5% drop in a week reflects intensifying GLP-1 competition and semaglutide risks, but its broad pipeline offers potential long-term growth.

Danish drugmaker Novo Nordisk (NVO) and Orbis Medicines struck an up to $1.4 billion licensing deal

Corbus Pharmaceuticals' positive obesity data boosts its cannabinoid strategy, while CRB-701 and cash needs add key context for investors.

Novo Nordisk (NYSE:NVO) has published results from its phase 3b FRONTIER5 study of investigational treatment denecimig in the Journal of Thrombosis and Haemostasis, reporting safety, laboratory and patient-experience findings in people with haemophilia A. The study examined whether patients could switch directly from emicizumab to denecimig without requiring a washout period or an initial loading dose.

The weight loss market is highly competitive, but Viking only needs to carve out a small niche in it with VK2735 in order to generate significant value for investors.

Eli Lilly and Novo Nordisk are vying for a new part of the weight loss drug market.

The Federal Reserve raised interest rates for the first time in three years, reversing cuts it made last year and implicitly countering the White House’s position that inflation isn’t a concern. Treasury yields moved higher after Fed Chairman Kevin Warsh began his post-decision press conference.

Novo Nordisk (NYSE:NVO) continues to draw attention from investors after a period of weaker share performance, with the stock down over the past month, past 3 months and year to date. At a share price of US$41.71, Novo Nordisk has seen momentum fade, with the 7 day share price return down 6.4% and the year to date share price return down 20.39%. The 1 year total shareholder return has declined 25.89%, pointing to a reassessment of both its growth potential and perceived risk. Compare Novo...

Novo Nordisk (NVO) closed the most recent trading day at $41.67, moving 2.02% from the previous trading session.

Anthropic's models may shorten research workflows, but neither company disclosed financial terms or productivity targets.

Healthcare stocks were slightly lower late Wednesday afternoon, with the NYSE Healthcare Index fract

Novo Nordisk partners with Anthropic on drug discovery. Here’s what the strategic alliance means for NVO shares.